US OptionsDetailed Quotes
ARQT240719C10000
- 0.65
- -0.18-21.69%
15min DelayClose Jul 2 16:00 ET
0.85High0.50Low
0.85Open0.83Pre Close286 Volume6.75K Open Interest10.00Strike Price18.14KTurnover118.86%IV14.52%PremiumJul 19, 2024Expiry Date0.00Intrinsic Value100Multiplier16DDays to Expiry0.65Extrinsic Value100Contract SizeAmericanOptions Type0.4411Delta0.1666Gamma13.78Leverage Ratio-0.0288Theta0.0016Rho6.08Eff Leverage0.0079Vega
Arcutis Biotherapeutics Stock Discussion
Sign in to post a comment
$Arcutis Biotherapeutics(ARQT.US$ News… Good/Bad ? neutral
2
$Arcutis Biotherapeutics(ARQT.US$ Holding 💎 nothing but holiday sellin
2
to the moon
🔥 July: 3 PDUFAs & 1 AdCom
$Arcutis Biotherapeutics(ARQT.US$ : ARQ-151 topical roflumilast cream
$Phathom Pharmaceuticals(PHAT.US$ : VOQUEZNA® (vonoprazan)
$AstraZeneca(AZN.US$ : Imfinzi + chemotherapy - AdCom
$BeiGene(BGNE.US$ : TEVIMBRA (tislelizumab)
$Arcutis Biotherapeutics(ARQT.US$ : ARQ-151 topical roflumilast cream
$Phathom Pharmaceuticals(PHAT.US$ : VOQUEZNA® (vonoprazan)
$AstraZeneca(AZN.US$ : Imfinzi + chemotherapy - AdCom
$BeiGene(BGNE.US$ : TEVIMBRA (tislelizumab)
5
1
$Arcutis Biotherapeutics(ARQT.US$ shorties making it go down but such a strong company. Applaud 👏🏻👏🏻👏🏻
2
What do we get out of the options and the stocks?
Is it merely money? Or is it happiness from the knowledge that we have obtained?
Is it merely money? Or is it happiness from the knowledge that we have obtained?
loading...
2
4
$Arcutis Biotherapeutics(ARQT.US$ anyone know why this stock is being murdered?
4
$Arcutis Biotherapeutics(ARQT.US$
I expect this to do well today based on its good ER results
I expect this to do well today based on its good ER results
4
3
$Arcutis Biotherapeutics(ARQT.US$
NEWS
Positive
Q1 2024 net product revenues of $21.6M, a 675% increase from Q1 2023.
ZORYVE cream and foam contributed $15M and $6.5M to revenues respectively.
Significant demand for ZORYVE products with 208,000 cream prescriptions and 46,000 foam prescriptions.
Raised $172.5M from a public offering.
Strategic licensing agreement in Japan with Sato Pharmaceutical.
FDA accepted sNDA for roflumilast cream for atopic dermatitis with a PDUFA date of July 7, 2024.
Ca...
NEWS
Positive
Q1 2024 net product revenues of $21.6M, a 675% increase from Q1 2023.
ZORYVE cream and foam contributed $15M and $6.5M to revenues respectively.
Significant demand for ZORYVE products with 208,000 cream prescriptions and 46,000 foam prescriptions.
Raised $172.5M from a public offering.
Strategic licensing agreement in Japan with Sato Pharmaceutical.
FDA accepted sNDA for roflumilast cream for atopic dermatitis with a PDUFA date of July 7, 2024.
Ca...
4
No comment yet
Benjamin’sOP : $Aquestive Therapeutics (AQST.US)$
Aestheticstonks : havent releaswd anything yet